Sorafenib as Adjuvant Therapy Post–Liver Transplant: A Single-center Experience
Background. Hepatocellular carcinoma (HCC) has a rising incidence and mortality in North America. Liver transplantation (LT) with adjunctive therapies offers excellent outcomes. However, HCC recurrences are associated with high mortality. We investigate whether adjuvant systemic therapy can reduce r...
Saved in:
Main Authors: | Hala Hassanain, MD, Ashton A. Connor, MD, PhD, Elizabeth W. Brombosz, PhD, Khush Patel, MD, MS, Ahmed Elaileh, MD, Tamneet Basra, MD, Sudha Kodali, MD, MSPH, David W. Victor, III, MD, Caroline J. Simon, MD, Yee Lee Cheah, MD, Mark J. Hobeika, MD, Constance M. Mobley, MD, PhD, Ashish Saharia, MD, Sadhna Dhingra, MD, Mary Schwartz, MD, Anaum Maqsood, MD, Kirk Heyne, MD, Ahmed O. Kaseb, MD, Jean-Nicolas Vauthey, MD, A. Osama Gaber, MD, Maen Abdelrahim, MD, PhD, R. Mark Ghobrial, MD, PhD |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer
2025-02-01
|
Series: | Transplantation Direct |
Online Access: | http://journals.lww.com/transplantationdirect/fulltext/10.1097/TXD.0000000000001746 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Solid Predominant Histology and High Podoplanin Expression in Cancer-Associated Fibroblast Predict Primary Resistance to Osimertinib in EGFR-Mutated Lung Adenocarcinoma
by: Yuji Uehara, MD, et al.
Published: (2025-03-01) -
Placental Vascular Malperfusion in Pregnancies With Congenital Heart Disease
by: Nour Rahnama, MD, et al.
Published: (2025-03-01) -
EGFR-Mutated Lung Adenocarcinoma With Li–Fraumeni Syndrome: The Imperative for Germline Testing in Patients With a Family History, a Case Report
by: Hiroyuki Fujii, MD, et al.
Published: (2025-02-01) -
A Phase I/II Study of Ultra-Hypofractionated Carbon-ion Radiation therapy for Low- and Intermediate-Risk Localized Prostate Cancer
by: Noriyuki Okonogi, MD, PhD, et al.
Published: (2025-03-01) -
Pembrolizumab and Pemetrexed for Older Patients With Nonsquamous NSCLC and Programmed Cell Death-Ligand 1 Tumor Proportion Scores of Less Than 50%
by: Yoshihito Kogure, MD, PhD, et al.
Published: (2025-03-01)